Figure 1

WFDC1 expression in the healthy and cancerous prostate. (A) WFDC1 expression is reduced in prostate cancer. The oncomine database was queried for the expression of WFDC1 in healthy control samples (HC) vs adenocarcinoma samples (prostate cancer (PCa)) from seven data sets (named) and the collated total data set. The bars represent 25–75% interval of normalised WFDC1 expression levels in each group. The deviation lines represent 10–90%. (B) Plot shows the frequency of deep WFDC1 deletions from seven data sets and the mean. (C) Data show the expression of WFDC1 in the four predominant cell types in the prostate. Data were mined from microarray performed previously by Oudes et al (2006), wherein cell suspensions was prepared from radical prostatectomies (n=5) and magnetic-activated cell sorting (MACS) sorted according to the expression of integrin β4, (basal) dipeptidyl peptidase IV (luminal secretory), integrin α1 (stromal fibromuscular) and platelet endothelial cell adhesion molecule-1 (PECAM-1) (endothelial) as described therein. (D) Quantitative PCR (qPCR) was used to assess WFDC1 and SLPI expression in commonly studied PCa-derived cell lines and HeLa. *P<0.05 and ***P<0.0001 by unpaired T-test (A, two-tailed; C, one-tailed). NS, nonsignificant.